Here, we demonstrate in ER<sup>+</sup> PyMT-BO1 and triple-negative 4T1 murine models that ribociclib (LEE011) monotherapy reduces primary mammary fat pad (MFP) tumor burden through a mechanism partially dependent on CD8<sup>+</sup> T cell function. Here, CD8A is linked to neoplasm.